Mechanistic Insights into Pseudomonas aeruginosa Resistance to Ceftolozane via PK/PD Modeling

Study Background and Research Question

Multidrug-resistant (MDR) Pseudomonas aeruginosa poses a major clinical challenge, particularly with rising resistance to key β-lactam/β-lactamase inhibitor combinations such as ceftolozane/tazobactam. While Ceftolozane sulfate displays potent bactericidal activity against P. aeruginosa and is widely used in both clinical and experimental settings, emergence of resistance during therapy has been repeatedly observed. The reference study (Deroche et al., 2023) addresses a key gap: how do specific mutations in ampC and ampD genes quantitatively alter susceptibility to ceftolozane-tazobactam, and what are the mechanisms of both acquired and adaptive resistance?

Key Innovation from the Reference Study

The primary innovation lies in the application of semi-mechanistic pharmacokinetic/pharmacodynamic (PK/PD) modeling to dissect the individual and combined contributions of ampC (G183D) and ampD (H157Y) mutations in P. aeruginosa. Rather than relying solely on minimum inhibitory concentration (MIC) values, the study leverages sequential time-kill experiments and dynamic modeling to differentiate between initial resistance and time-dependent (adaptive) resistance phenomena. This quantitative framework allows for precise attribution of resistance phenotypes to specific genetic backgrounds and provides clarity on the reversibility of resistance and collateral effects on other antibiotics such as imipenem.

Methods and Experimental Design Insights

To unravel the genetic basis and kinetics of resistance, the authors engineered isogenic strains of P. aeruginosa PAO1 with either single or combined ampC and ampD mutations through homologous recombination. Clinical isolates were also analyzed to confirm findings in a relevant background. Sequential time-kill curve experiments—benchmarks of in vitro antibacterial susceptibility assay workflows—were performed for each strain under varying drug exposures. Semi-mechanistic PK/PD models, incorporating both bacterial growth and antibiotic-induced killing/adaptation, were fitted to the data to estimate EC₅₀ (half-maximal effective concentration) changes over time. This approach allows the modeling of both acquired and adaptive resistance dynamics, a significant advance over static MIC-based methodologies.

Protocol Parameters

• Strain construction: Homologous recombination to introduce G183D in ampC, H157Y in ampD, or both, in PAO1 and clinical backgrounds.
• In vitro time-kill assays: Sequential exposure of bacterial cultures to ceftolozane-tazobactam at clinically relevant concentrations; sampling at multiple timepoints.
• PK/PD modeling: Use of semi-mechanistic models accounting for adaptation, estimating EC₅₀ and adaptation rates for each genetic variant.
• Susceptibility testing: Cation-adjusted Mueller-Hinton broth, with ceftolozane concentrations spanning 0.03–32 mg/L, per established protocols (product specification).
• Comparative antibiotic testing: Parallel assessment of imipenem susceptibility to evaluate collateral effects of mutations.

Core Findings and Why They Matter

The study demonstrates that both ampC and ampD mutations contribute additively to resistance, with the combined mutant (AmpC_G183D/AmpD_H157Y) displaying a 29-fold increase in initial EC₅₀ and an even greater (up to 320-fold) adaptive resistance over time compared to wild-type PAO1. These changes are quantitatively resolved using PK/PD modeling, revealing that the double mutant is substantially more resistant than either single mutant throughout the course of drug exposure. Strikingly, reversal of these mutations in clinical isolates restored ceftolozane susceptibility, with EC₅₀ dropping from 80.5 mg/L to 6.77 mg/L. The adaptive resistance component—where susceptibility further declines during prolonged exposure—could not be captured by static MIC measurements, underscoring the value of dynamic PK/PD analysis.

A notable collateral effect was observed: while ampC (G183D) mutation drove ceftolozane resistance, it also restored imipenem susceptibility, highlighting a trade-off in resistance mechanisms. The modeling approach allowed clear discrimination between the effects of acquired versus adaptive resistance, an essential consideration for translational research and clinical decision-making.

Comparison with Existing Internal Articles

These findings extend the framework established in previous analyses of ceftolozane resistance. For example, "Unraveling Ceftolozane Resistance in P. aeruginosa: PK/PD Modeling Insights" provides a systematic overview of how specific mutations impact drug efficacy via modeling, while "Ceftolozane Sulfate: Protocol Optimization for Antibacterial Research" offers practical workflow guidance for in vitro and in vivo assays using ceftolozane sulfate. The current study advances these foundations by quantifying adaptive resistance and demonstrating the reversibility of resistance phenotypes upon genetic reversion. Additionally, "Ceftolozane Sulfate: Optimizing PK/PD Studies and Resistance Testing" emphasizes the importance of dynamic PK/PD-driven design, which the reference study operationalizes through its advanced modeling strategy.

Limitations and Transferability

While the semi-mechanistic PK/PD modeling approach offers high-resolution insights into resistance mechanisms, several limitations warrant mention. The study's engineered and clinical strains represent specific mutational backgrounds; resistance in real-world settings may involve additional or alternative mechanisms. Furthermore, the in vitro time-kill assay conditions, while standardized, do not fully replicate the complexities of host environments or immune responses. Translation of PK/PD model parameters from laboratory to clinical context requires validation in animal models—such as the neutropenic mouse thigh infection model—and ultimately in patient populations. The approach, however, is broadly transferable for dissecting resistance in other Gram-negative pathogens and can be adapted for high-throughput screening of novel compounds or combination regimens.

Research Support Resources

For researchers aiming to replicate or extend these PK/PD and resistance studies, Ceftolozane sulfate (SKU C8753, APExBIO) is available as a stable, high-purity reagent suitable for both in vitro and animal model workflows. Published protocols recommend using cation-adjusted Mueller-Hinton broth and validated concentration ranges (0.03–32 mg/L) for susceptibility testing, with dynamic PK/PD modeling to capture both acquired and adaptive resistance phenomena. Further protocol refinement and troubleshooting strategies are outlined in several internal resources, including "Ceftolozane Sulfate: Protocol Optimization for Antibacterial Research" and "Ceftolozane Sulfate: Optimizing PK/PD Studies and Resistance Testing." These can assist research teams in maximizing experimental reproducibility and translational impact.